{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:18:42Z","timestamp":1788265122615,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    The gut microbiota is a critical regulator of systemic immune homeostasis; accumulating evidence implicates specific commensal bacteria, termed \u201cpathobionts,\u201d in autoimmune disease pathogenesis. However, the definition of pathobionts remains context-dependent, as their effects are influenced by host genetics and host\u2013microbe interactions. In this review, we summarize representative pathobionts supported by functional evidence in selected extraintestinal autoimmune diseases and discuss how these mechanisms may inform phage-based microbiome-targeted interventions. Mechanistically, pathobionts contribute to autoimmune disease through multiple pathways, including molecular mimicry, induction of intestinal T helper 17 and T follicular helper cell responses, disruption of regulatory T cell homeostasis, intestinal barrier dysfunction, and bacterial translocation from the gut to extraintestinal sites. These processes highlight the central role of gut-associated lymphoid tissue in initiating systemic autoimmunity, and targeting disease-associated microbes represents a promising therapeutic strategy. Whole-phage therapy, which enables highly specific bacterial elimination, has shown efficacy in preclinical immune-mediated disease models, but may be affected by variable\n                    <jats:italic>in vivo<\/jats:italic>\n                    replication, bacterial receptor-mediated resistance, anti-phage immune responses, and ecological effects on the resident microbiome. Phage-derived enzymes that lyse bacterial cell walls, such as endolysins, represent a complementary therapeutic modality that specifically targets bacterial peptidoglycan through cell wall-binding and catalytic domains. Collectively, these findings support the concept that pathobiont-targeted interventions, particularly phage-based strategies, may provide microbiome-directed, immunosuppression-sparing therapeutic approaches for selected patient subsets.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2026.1884094","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:47:51Z","timestamp":1788263271000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Autoimmune disease-associated pathobionts: mechanisms and therapeutic potential of phage-based approaches"],"prefix":"10.3389","volume":"17","author":[{"given":"Kentaro","family":"Kuzuya","sequence":"first","affiliation":[{"name":"Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka","place":["Osaka, Japan"]},{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka","place":["Osaka, Japan"]},{"name":"Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, The University of Osaka","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosuke","family":"Fujimoto","sequence":"additional","affiliation":[{"name":"Department of Microbial Regulation, Research Institute for Microbial Diseases, The University of Osaka","place":["Osaka, Japan"]},{"name":"Department of Immunology and Genomics, Osaka Metropolitan University Graduate School of Medicine","place":["Osaka, Japan"]},{"name":"Division of Metagenome Medicine, Human Genome Center, The Institute of Medical Science, The University of Tokyo","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro2315","article-title":"Bacteriophage resistance mechanisms","volume":"8","author":"Labrie","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"141","DOI":"10.3390\/v9060141","article-title":"The human gut phage community and its implications for health and disease","volume":"9","author":"Manrique","year":"2017","journal-title":"Viruses"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2023.04.008","article-title":"Immunogenicity of bacteriophages","volume":"31","author":"Champagne-Jorgensen","year":"2023","journal-title":"Trends Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-virology-091919-074551","article-title":"Bacteriophages and the immune system","volume":"8","author":"Popescu","year":"2021","journal-title":"Annu Rev Virol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2025.2597614","article-title":"Extensive cultivation of human gut phages revealing undescribed Bacteroidaceae phages","volume":"17","author":"Liu","year":"2025","journal-title":"Gut Microbes"},{"key":"B6","doi-asserted-by":"publisher","first-page":"5252","DOI":"10.1038\/s41467-022-32832-w","article-title":"Extensive gut virome variation and its associations with host and environmental factors in a population-level cohort","volume":"13","author":"Nishijima","year":"2022","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01705-x","article-title":"Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study","volume":"9","author":"Pirnay","year":"2024","journal-title":"Nat Microbiol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03678-8","article-title":"Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"31","author":"Chan","year":"2025","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu Rev Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.tim.2020.04.011","article-title":"Label or concept - what is a pathobiont","volume":"28","author":"Jochum","year":"2020","journal-title":"Trends Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01420","article-title":"Complex bacterial consortia reprogram the colitogenic activity of Enterococcus faecalis in a gnotobiotic mouse model of chronic, immune-mediated colitis","volume":"10","author":"Lengfelder","year":"2019","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.11.5157-5166.1998","article-title":"Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism","volume":"66","author":"Kullberg","year":"1998","journal-title":"Infect Immun"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2017.11.002","article-title":"A large polysaccharide produced by Helicobacter hepaticus induces an anti-inflammatory gene signature in macrophages","volume":"22","author":"Danne","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/nature25019","article-title":"Moving beyond microbiome-wide associations to causal microbe identification","volume":"552","author":"Surana","year":"2017","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1711235114","article-title":"Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models","volume":"114","author":"Cekanaviciute","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2120028119","article-title":"A gut microbial peptide and molecular mimicry in the pathogenesis of type 1 diabetes","volume":"119","author":"Girdhar","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06754-x","article-title":"Association between primary Sj\u00f6gren's syndrome and gut microbiota disruption: a systematic review and meta-analysis","volume":"43","author":"Shen","year":"2024","journal-title":"Clin Rheumatol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1053\/j.gastro.2023.09.019","article-title":"Pathobionts in inflammatory bowel disease: origins, underlying mechanisms, and implications for clinical care","volume":"166","author":"Gilliland","year":"2024","journal-title":"Gastroenterology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"18001","DOI":"10.1038\/nrdp.2018.1","article-title":"Rheumatoid arthritis","volume":"4","author":"Smolen","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01154-0","article-title":"Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis","volume":"20","author":"Holers","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"Elife"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/art.39783","article-title":"Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine","volume":"68","author":"Maeda","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222881","article-title":"Genomic repertoires linked with pathogenic potency of arthritogenic Prevotella copri isolated from the gut of patients with rheumatoid arthritis","volume":"82","author":"Nii","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.116755","article-title":"Mucosal innate immune activation as the trigger to Prevotella species-induced arthritis in genetically resistant mice","volume":"45","author":"Maeda","year":"2026","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-01898-7","article-title":"The immunology of systemic lupus erythematosus","volume":"25","author":"Tsokos","year":"2024","journal-title":"Nat Immunol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01071-8","article-title":"The gut microbiome in systemic lupus erythematosus: lessons from rheumatic fever","volume":"20","author":"Silverman","year":"2024","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar7201","article-title":"Translocation of a gut pathobiont drives autoimmunity in mice and humans","volume":"359","author":"Manfredo Vieira","year":"2018","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj6294","article-title":"Translocating gut pathobiont Enterococcus gallinarum induces T(H)17 and IgG3 anti-RNA-directed autoimmunity in mouse and human","volume":"17","author":"Gronke","year":"2025","journal-title":"Sci Transl Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04949-x","article-title":"Within-host evolution of a gut pathobiont facilitates liver translocation","volume":"607","author":"Yang","year":"2022","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214856","article-title":"Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal","volume":"78","author":"Azzouz","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.897971","article-title":"Sex-dependent lupus Blautia (Ruminococcus) gnavus strain induction of zonulin-mediated intestinal permeability and autoimmunity","volume":"13","author":"Silverman","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/acr2.70033","article-title":"Gut expansion of a human lupus pathobiont is associated with autoantibody production and T cell dysregulation","volume":"7","author":"Ma","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220687","article-title":"Metagenome-wide association study revealed disease-specific landscape of the gut microbiome of systemic lupus erythematosus in Japanese","volume":"80","author":"Tomofuji","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","first-page":"SI4","DOI":"10.1093\/rheumatology\/kead603","article-title":"Antiphospholipid syndrome pathogenesis in 2023: an update of new mechanisms or just a reconsideration of the old ones","volume":"63","author":"Raschi","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2019.05.003","article-title":"Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity","volume":"26","author":"Ruff","year":"2019","journal-title":"Cell Host Microbe"},{"key":"B37","doi-asserted-by":"publisher","first-page":"a28685248","DOI":"10.1055\/a-2868-5248","article-title":"Cross-reactivity of antiphospholipid antibodies with gut commensal proteins in antiphospholipid syndrome","volume":"10","author":"van Mourik","year":"2026","journal-title":"TH Open"},{"key":"B38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41572-025-00600-x","article-title":"Primary sclerosing cholangitis","volume":"11","author":"Manns","year":"2025","journal-title":"Nat Rev Dis Primers"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-022-00690-y","article-title":"The microbiota and the gut-liver axis in primary sclerosing cholangitis","volume":"20","author":"Hov","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2025.101716","article-title":"Geography-independent mucosal microbiota alterations in primary sclerosing cholangitis persist after liver transplantation","volume":"8","author":"Bajer","year":"2026","journal-title":"JHEP Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/s41564-018-0333-1","article-title":"Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis","volume":"4","author":"Nakamoto","year":"2019","journal-title":"Nat Microbiol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.104055","article-title":"Gut dysbiosis in rheumatic diseases: a systematic review and meta-analysis of 92 observational studies","volume":"80","author":"Wang","year":"2022","journal-title":"EBioMedicine"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2306","article-title":"Commensal orthologs of the human autoantigen Ro60 as triggers of autoimmunity in lupus","volume":"10","author":"Greiling","year":"2018","journal-title":"Sci Transl Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.03.013","article-title":"Gut microbiota drive autoimmune arthritis by promoting differentiation and migration of Peyer's patch T follicular helper cells","volume":"44","author":"Teng","year":"2016","journal-title":"Immunity"},{"key":"B45","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41590-025-02125-7","article-title":"Aberrant T follicular helper cells generated by T(H)17 cell plasticity in the gut promote extraintestinal autoimmunity","volume":"26","author":"Fan","year":"2025","journal-title":"Nat Immunol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04642-z","article-title":"TLR7 gain-of-function genetic variation causes human lupus","volume":"605","author":"Brown","year":"2022","journal-title":"Nature"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1187145","article-title":"TLR7\/TLR8 activation and susceptibility genes synergize to breach gut barrier in a mouse model of lupus","volume":"14","author":"Ma","year":"2023","journal-title":"Front Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.07.003","article-title":"Targeted suppression of human IBD-associated gut microbiota commensals by phage consortia for treatment of intestinal inflammation","volume":"185","author":"Federici","year":"2022","journal-title":"Cell"},{"key":"B49","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1038\/s41467-023-39029-9","article-title":"Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis","volume":"14","author":"Ichikawa","year":"2023","journal-title":"Nat Commun"},{"key":"B50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12916-024-03303-4","article-title":"Efficacy and safety of gut microbiota-based therapies in autoimmune and rheumatic diseases: a systematic review and meta-analysis of 80 randomized controlled trials","volume":"22","author":"Zeng","year":"2024","journal-title":"BMC Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1111\/1756-185X.12333","article-title":"Effects of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients: a randomized double-blind clinical trial","volume":"17","author":"Alipour","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2022.102844","article-title":"Safety and efficacy of fecal microbiota transplantation for treatment of systemic lupus erythematosus: An EXPLORER trial","volume":"130","author":"Huang","year":"2022","journal-title":"J Autoimmun"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01014-8","article-title":"Short-chain fatty acids: linking diet, the microbiome and immunity","volume":"24","author":"Mann","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/frmbi.2024.1441290","article-title":"Navigating regulatory and analytical challenges in live biotherapeutic product development and manufacturing","volume":"3","author":"Barberio","year":"2024","journal-title":"Front Microbiomes"},{"key":"B56","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40560-024-00759-7","article-title":"Current status of bacteriophage therapy for severe bacterial infections","volume":"12","author":"Sawa","year":"2024","journal-title":"J Intensive Care"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmp.2025.11.003","article-title":"Bacterial resistance to phage therapy: Mechanisms and strategies to overcome it","volume":"18","author":"Karamlou","year":"2025","journal-title":"Curr Mol Pharmacol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.06.005","article-title":"Metagenome data on intestinal phage-bacteria associations aids the development of phage therapy against pathobionts","volume":"28","author":"Fujimoto","year":"2020","journal-title":"Cell Host Microbe"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07667-8","article-title":"An enterococcal phage-derived enzyme suppresses graft-versus-host disease","volume":"632","author":"Fujimoto","year":"2024","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2025.1603380","article-title":"Endolysins and membrane-active peptides: innovative engineering strategies against gram-negative bacteria","volume":"16","author":"Wojciechowska","year":"2025","journal-title":"Front Microbiol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1128\/JB.181.16.4725-4733.1999","article-title":"Structures of gram-negative cell walls and their derived membrane vesicles","volume":"181","author":"Beveridge","year":"1999","journal-title":"J Bacteriol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11070966","article-title":"Immunogenicity of endolysin PlyC","volume":"11","author":"Harhala","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"B63","doi-asserted-by":"publisher","first-page":"680","DOI":"10.3390\/v13040680","article-title":"The advantages and challenges of using endolysins in a clinical setting","volume":"13","author":"Murray","year":"2021","journal-title":"Viruses"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1186\/s12929-023-00919-1","article-title":"Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria","volume":"30","author":"Liu","year":"2023","journal-title":"J Biomed Sci"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/nature01026","article-title":"A bacteriolytic agent that detects and kills Bacillus anthracis","volume":"418","author":"Schuch","year":"2002","journal-title":"Nature"},{"key":"B66","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.mib.2008.09.012","article-title":"Bacteriophage lysins as effective antibacterials","volume":"11","author":"Fischetti","year":"2008","journal-title":"Curr Opin Microbiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"105844","DOI":"10.1016\/j.ijantimicag.2019.11.001","article-title":"Endolysins as emerging alternative therapeutic agents to counter drug-resistant infections","volume":"55","author":"Gondil","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"B68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/antibiotics7010017","article-title":"Potential for bacteriophage endolysins to supplement or replace antibiotics in food production and clinical care","volume":"7","author":"Love","year":"2018","journal-title":"Antibiotics (Basel)"},{"key":"B69","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/antibiotics10020124","article-title":"Phage-encoded endolysins","volume":"10","author":"Abdelrahman","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05261-22","article-title":"The lysin exebacase has a low propensity for resistance development in Staphylococcus aureus and suppresses the emergence of resistance to antistaphylococcal antibiotics","volume":"11","author":"Oh","year":"2023","journal-title":"Microbiol Spectr"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02927","article-title":"Improved biodistribution and extended serum half-life of a bacteriophage endolysin by albumin binding domain fusion","volume":"9","author":"Seijsing","year":"2018","journal-title":"Front Microbiol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1385261","article-title":"Endolysins: a new antimicrobial agent against antimicrobial resistance. Strategies and opportunities in overcoming the challenges of endolysins against Gram-negative bacteria","volume":"15","author":"Khan","year":"2024","journal-title":"Front Pharmacol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2024.2387144","article-title":"Phage lysins for intestinal microbiome modulation: current challenges and enabling techniques","volume":"16","author":"Pottie","year":"2024","journal-title":"Gut Microbes"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1016\/j.mib.2024.102433","article-title":"Gram-negative endolysins: overcoming the outer membrane obstacle","volume":"78","author":"Sisson","year":"2024","journal-title":"Curr Opin Microbiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41579-023-00998-9","article-title":"Utilization of the microbiome in personalized medicine","volume":"22","author":"Ratiner","year":"2024","journal-title":"Nat Rev Microbiol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for human gut microbiota research","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis Model Mech"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-025-01041-3","article-title":"A Consensus Statement on establishing causality, therapeutic applications and the use of preclinical models in microbiome research","volume":"22","author":"Metwaly","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1713471","article-title":"Regulatory considerations for developing phage therapy medicinal products for the treatment of antimicrobial resistant bacterial infections","volume":"16","author":"Fukaya-Shiba","year":"2025","journal-title":"Front Pharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884094\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:47:52Z","timestamp":1788263272000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1884094\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":78,"alternative-id":["10.3389\/fimmu.2026.1884094"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1884094","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"1884094"}}